ThirdAge

<img alt="" height="1" width="1" />
Gilead HIV drug meets study goal
BusinessWeek
Gilead Sciences Inc. said Wednesday its potential HIV treatment elvitegravir met its key goals in a late-stage study. Its shares rose 41 cents to $40.85 in morning trading. Patients received once-daily doses of the drug candidate over a 48-week period ...
Gilead Takes Small but Important Step With HIV TherapySeeking Alpha
Gilead Sciences Preps $1 Billion Bond IssueWall Street Journal
Gilead HIV drug meets study goalForbes
Reuters -Medical News Today -NASDAQ
all 92 news articles &raquo;


More...